STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDGL
  4. [144] Madrigal Pharmaceuticals, Inc. SEC Filing

[144] Madrigal Pharmaceuticals, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock MDGL logo
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

#1482 Ranked by Market Cap
N/A Ranked by Dividends

MDGL Latest News

Jul 16, 2025
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Jul 16, 2025
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)
Jun 20, 2025
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
Jun 17, 2025
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Jun 2, 2025
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference

MDGL Latest SEC Filings

Jul 18, 2025
[144] Madrigal Pharmaceuticals, Inc. SEC Filing
Jul 18, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 18, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 17, 2025
[144] Madrigal Pharmaceuticals, Inc. SEC Filing
Jul 17, 2025
[144] Madrigal Pharmaceuticals, Inc. SEC Filing

MDGL Stock Data

6.99B
20.43M
8.74%
105.1%
17%
Biotechnology
Pharmaceutical Preparations
Link
United States
WEST CONSHOHOCKEN